Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disruptive Pharma ABOSTO:DPHA +0.83%4 EV-to-EBITDA is -0.94 as of Sep. 22, 2026. GuruFocus rates OSTO:DPHA with a GF Score™ of 4/100. Among 745 Drug Manufacturers companies, Disruptive Pharma AB ranks worse than 134228.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Disruptive Pharma AB's enterprise value is kr49.87 Mil.
Disruptive Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr-53.13 Mil. Therefore, Disruptive Pharma AB's EV-to-EBITDA for today is -0.94.
The historical rank and industry rank for Disruptive Pharma AB's EV-to-EBITDA or its related term are showing as below:
OSTO:DPHA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.97 Med: 0 Max: 0
Current: -2.54
OSTO:DPHA's EV-to-EBITDA is ranked worse than 100% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs OSTO:DPHA: -2.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Disruptive Pharma AB (OSTO:DPHA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Disruptive Pharma AB's PE Ratio (TTM) for today is calculated as:
Disruptive Pharma AB's share price for today is kr1.21.
Disruptive Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.634.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Disruptive Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disruptive Pharma AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Disruptive Pharma AB's EV-to-EBITDA falls into.
Disruptive Pharma AB's current Enterprise Value is kr49.87 Mil.
Disruptive Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-53.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disruptive Pharma AB (OSTO:DPHA) has a EV-to-EBITDA of -0.94 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Disruptive Pharma AB. According to the industry distribution chart, Disruptive Pharma AB ranks #999999 out of 745 companies in the Drug Manufacturers industry.
Is Disruptive Pharma AB's EV-to-EBITDA too high?
Disruptive Pharma AB's current EV-to-EBITDA is -0.94. Based on the distribution chart, Disruptive Pharma AB ranks #999999 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's EV-to-EBITDA compare to ?
According to the Drug Manufacturers industry distribution chart, Disruptive Pharma AB ranks #999999 out of 745 companies for EV-to-EBITDA. This places Disruptive Pharma AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Disruptive Pharma AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disruptive Pharma AB's current EV-to-EBITDA is -0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (OSTO:DPHA) has a current EV-to-EBITDA of -0.94. The current EV-to-EBITDA is -0.94. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Disruptive Pharma AB (OSTO:DPHA), the current EV-to-EBITDA is -0.94 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score
Get the complete analysis for OSTO:DPHA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DPHA has been successfully added to your 
